Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Siltuximab [USAN:INN]
RN: 541502-14-1


  • A chimeric anti-interleukin-6 antibody for treatment of multiple myeloma and renal cell carcinoma; in phase I and phase II clinical trials.

    NCI: A human-mouse chimeric antibody, constructed from a murine antiinterleukin 6 (IL-6) monoclonal antibody, with antitumor and antiinflammatory activities. Containing the antigen-binding variable region of the murine antibody, CLB-IL-6-8, and the constant region of a human IgG1kappa immunoglobulin, siltuximab has high affinity for recombinant as well as native IL-6 and inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), resulting in the blockade of the IL-6/IL-6R/gp130 signal transduction pathway, and, subsequently, antitumor and antiinflammatory activities. (NCI Thesaurus)

Molecular Formula

  • C6450-H9932-N1688-O2016-S50

Classification Codes

  • Antineoplastic
  • Antineoplastic Agents

Names and Synonyms

Name of Substance

  • Siltuximab [USAN:INN]


  • CNTO 328
  • CNTO-328
  • Immunoglobulin G1, anti-(human interleukin 6 (BSF-2, interferon beta-2)); human mouse chimeric monoclonal CNTO 328 gamma1 heavy chain (222-213')-disulfide with human mouse chimeric monoclonal CNTO 328 kappa light chain, dimer (228-228'':231-231'')- bisdisulfide
  • Siltuximab
  • Sylvant

Systematic Name

  • Immunoglobulin G1, anti-(human interleukin 6) (human-mouse monoclonal CNTO 328 heavy chain), disulfide with human-mouse monoclonal CNTO 328 kappa-chain, dimer

Registry Numbers

CAS Registry Number

  • 541502-14-1


  • T4H8FMA7IM

System Generated Number

  • 0541502141